MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.46 0.14

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.45

Max

21.47

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -21M
Pardavimai	14M 54M
Pelno marža	-39.611
Darbuotojai	178
EBITDA	-3.8M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-2.71% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B 2.2B
Ankstesnė atidarymo kaina	21.32
Ankstesnė uždarymo kaina	21.46

Naujienos nuotaikos

By Acuity

50%

161 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB: Higher Energy Prices to Raise Production, Consumer Costs

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

2026-04-10 00:00; UTC

Svarbiausios naujienos

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

2026-04-09 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026-04-09 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

2026-04-09 23:14; UTC

Rinkos pokalbiai

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

2026-04-09 23:14; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-09 23:07; UTC

Rinkos pokalbiai

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

2026-04-09 22:54; UTC

Rinkos pokalbiai

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

2026-04-09 22:31; UTC

Svarbiausios naujienos

Trump on Truth Social: 'That Is Not the Agreement We Have!'

2026-04-09 22:31; UTC

Svarbiausios naujienos

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

2026-04-09 20:57; UTC

Svarbiausios naujienos

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

2026-04-09 20:55; UTC

Uždarbis

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

2026-04-09 20:55; UTC

Uždarbis

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

2026-04-09 20:55; UTC

Uždarbis

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

2026-04-09 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-09 20:40; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

2026-04-09 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

2026-04-09 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Rowan Digital Infrastructure Announces Strategic Recapitalization

2026-04-09 20:25; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

2026-04-09 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-09 19:30; UTC

Svarbiausios naujienos

How Digital Currencies Have Helped Iran -- WSJ

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-2.71% į apačią

12 mėnesių prognozė

Vidutinis 20.86 USD -2.71%

Aukščiausias 21.5 USD

Žemiausias 17 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

161 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.